← Back to Screener
Sensei Biotherapeutics, Inc. Common Stock (SNSE)
Price$14.65
Momentum ScoreC
Favorite Metrics
Price vs S&P 500 (26W)66.07%
Price vs S&P 500 (4W)-37.38%
VGM Score45.90
Market Capitalization$19.66M
All Metrics
Book Value / Share (Quarterly)$142.64
P/TBV (Annual)0.16x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-17.99
Price vs S&P 500 (YTD)29.14%
EPS (TTM)$-142.73
10-Day Avg Trading Volume0.05M
EPS Excl Extra (TTM)$-142.73
EPS (Annual)$-16.72
ROI (Annual)-112.92%
Cash / Share (Quarterly)$151.30
ROA (Last FY)-92.07%
EBITD / Share (TTM)$-146.11
ROE (5Y Avg)-63.32%
Cash Flow / Share (Annual)$-16.22
P/B Ratio0.10x
P/B Ratio (Quarterly)0.22x
Net Income / Employee (Annual)$-727,100
Net Interest Coverage (TTM)-28.13x
ROA (TTM)-256.50%
EPS Incl Extra (Annual)$-16.72
Current Ratio (Annual)5.06x
Quick Ratio (Quarterly)14.32x
3-Month Avg Trading Volume0.22M
52-Week Price Return108.10%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$2.84
52-Week High$36.76
EPS Excl Extra (Annual)$-16.72
CapEx CAGR (5Y)-57.90%
26-Week Price Return73.99%
Quick Ratio (Annual)5.00x
13-Week Price Return-51.97%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)14.39x
Enterprise Value$-132.65M
Revenue / Employee (Annual)$0
Cash / Share (Annual)$16.79
3-Month Return Std Dev112.44%
Net Income / Employee (TTM)$-6,360,600
ROE (Last FY)-113.41%
EPS Basic Excl Extra (Annual)$-16.72
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-142.73
ROI (TTM)-282.97%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$3.36
Price vs S&P 500 (52W)83.73%
Year-to-Date Return37.30%
5-Day Price Return-25.97%
EPS Normalized (Annual)$-16.72
ROA (5Y Avg)-53.89%
Month-to-Date Return-30.70%
Cash Flow / Share (TTM)$-1.28
EBITD / Share (Annual)$-17.57
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-62.33%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-142.73
P/TBV (Quarterly)0.23x
P/B Ratio (Annual)0.72x
Book Value / Share (Annual)$14.74
Price vs S&P 500 (13W)-60.22%
Beta-0.13x
Revenue / Share (TTM)$0.00
ROE (TTM)-283.67%
52-Week Low$5.60
mGradeC
vgmGradeC
Show chart for
Earnings Surprise History
Q1 26-28.79est. -0.63
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
2.17
2.17
4.13
4.20
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
SNSESensei Biotherapeutics, Inc. Common Stock | — | — | C | $14.65 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
Sensei Biotherapeutics is an immuno-oncology company developing next-generation cancer therapeutics through its TMAb (Tumor Microenvironment Activated Biologics) platform, which targets immunosuppressive and immunostimulatory signals within tumors. The company has four clinical-stage candidates in development: SNS-101 (VISTA), SNS-102 (VSIG4), SNS-103 (ENTPDase/CD39), and SNS-201 (VISTAxCD28). This targeted approach aims to improve outcomes for cancer patients by modulating the tumor microenvironment.